‘ΑWkeνΰΜͺqWIΓ@Μ»΅ΖWJlζ28ρφJuV|WEv
ε°ΰΜͺqWI‘Γ
Rc@xj1, ¬ς@ς1, im@½κ1, Όc@Ύv2, ΄@αY1, βδ@ρ3, ‘R@Ns1, c@Kχ1, γc@Nρ1, ΄@hξ1, xc@³[1, IR@γΔ1, Ό{@qi2, gc@°1
1ϊ{γΘεwΑ»νOΘw
2ϊ{γΘεwηtka@OΘ
3ϊ{γΘεw½iRa@OΘ
Molecular Target Therapy for Digestive Malignancy
Takeshi Yamada1, Michihiro Koizumi1, Seiichi Shinji1, Akihisa Matsuda2, Goro Takahashi1, Takuma Iwai3, Yasuyuki Yokoyama1, Kohki Takeda1, Kohji Ueda1, Keisuke Hara1, Masahiro Hotta1, Sho Kuriyama1, Satoshi Matsumoto2 and Hiroshi Yoshida1
1)Department of Gastrointestinal and Hepato-Billiary-Pancreatic Surgery, Nippon Medical School
2)Department of Surgery, Nippon Medical School Chiba Hokusoh Hospital
3)Department of Surgery, Nippon Medical School Tama Nagayama Hospital

ϊγεγο 2018; 14(4), 169-172
Key words
molecular target therapy, digestive cancer, anti-vascular endothelial growth factor (VEGF) antibody, anti-epidermal growth factor receptor (EGFR) antibody
Correspondence to
Takeshi Yamada, Department of Gastrointestinal and Hepato-Billiary-Pancreatic Surgery, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan
E-mailFy-tak@nms.ac.jp
σtF2018N87ϊ@σF2018N96ϊ |